Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells (scientific article published on 16 March 2020)

Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression

Q28219291

Arachidonic acid metabolism

Q28287622

Cyclooxygenases 1 and 2

Q29615645

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

Q29617192

Expression of cyclooxygenase 2 in human malignant melanoma.

Q31983368

Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia

Q34082384

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Q34477195

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

Q34547253

The role of nitric oxide in cancer

Q35045661

Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.

Q35289963

Morphological features of cell death

Q35773151

Treatment strategies for osteoarthritis patients with pain and hypertension

Q36059512

Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen

Q89922354

Synthesis and evaluation of carbaborane derivatives of indomethacin as cyclooxygenase inhibitors.

Q36105949

Ortho-carbaborane derivatives of indomethacin as cyclooxygenase (COX)-2 selective inhibitors

Q36129926

Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines

Q36179852

Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?

Q36185858

Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis

Q36488969

nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2

Q36987287

Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients

Q37211803

2-Carbaborane-3-phenyl-1H-indoles--synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity.

Q37361431

Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer

Q37602370

Carbaboranes as pharmacophores: properties, synthesis, and application strategies

Q37903836

Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro

Q38808841

Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer

Q38910265

Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells

Q38968834

ROS signalling in the biology of cancer.

Q39355072

A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth

Q39457346

Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells

Q39743712

The anti-proliferative potency of celecoxib is not a class effect of coxibs

Q39973144

Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines

Q40113431

Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).

Q40555630

COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro

Q40555637

Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation.

Q40559845

Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro

Q40597493

Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis

Q41595109

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.

Q42316726

Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.

Q43006328

Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization

Q43057500

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib

Q43770432

Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions

Q44017936

Metabolism of rofecoxib in vitro using human liver subcellular fractions

Q44626672

Asborin inhibits Aldo/Keto reductase 1A1.

Q44655249

Asborin: the carbaborane analogue of aspirin.

Q46072092

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

Q46365810

Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals

Q46713563

Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors.

Q50962818

A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice

Q70935075

Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates

Q72488009

Facile Synthesis and NO-Generating Property of 4H-[1,2,5]Oxadiazolo[3,4-d]pyrimidine-5,7-dione 1-Oxides

Q74838972

Design, synthesis, and evaluation of anti-inflammatory, analgesic, ulcerogenicity, and nitric oxide releasing studies of novel indomethacin analogs as non-ulcerogenic derivatives

Q82677772

P433

issue

P921

main subject

colon cancer

Q18555025

P304

page(s)

4827

P577

publication date